FDA Compliance Moves Upstream as i-GENTIC AI Expands GENIE Across the Full Lifecycle
i-GENTIC AI says it is expanding GENIE to support the full FDA compliance lifecycle for life sciences companies. The pitch reflects rising demand for software that can manage regulatory work continuously rather than as a one-off filing exercise. If the approach gains traction, it could turn compliance from a back-office burden into a more automated operating layer.
Regulatory software is quietly becoming one of the more strategic categories in healthcare AI. i-GENTIC AI’s expansion of GENIE is significant because it addresses a problem that every life sciences company knows well: compliance is not a single event, but a recurring, documentation-heavy process that spans development, submission, post-market obligations, and audit readiness.
The promise of a full lifecycle system is that it could reduce fragmentation. Many organizations still manage regulatory work across disconnected tools, spreadsheets, and human memory. If GENIE can consolidate that work and keep documentation aligned with evolving FDA expectations, it could lower risk while improving speed and consistency.
There is also a larger market signal here. As AI tools spread through regulated industries, buyers are demanding evidence that software can help them stay compliant, not merely productive. That shifts the value proposition away from flashy automation and toward reliability, traceability, and governance.
The challenge, of course, is trust. Compliance teams will not hand over critical workflows to a black box. The companies most likely to win in this space will be those that build systems around auditability, human review, and clear regulatory logic rather than generic automation claims.